No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Moderna, Inc. is a pioneering biotechnology firm dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) therapeutics and vaccines. Operating across the United States, Europe, and other international markets, the company addresses a wide spectrum of health challenges, including infectious diseases, immuno-oncology, rare disorders, cardiovascular conditions, and auto-immune diseases. Its extensive vaccine pipeline encompasses a variety of critical areas: respiratory pathogens such as COVID-19, influenza, respiratory syncytial virus (RSV), Endemic HCoV, and hMPV+PIV3; latent viruses like cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats including Zika and Nipah. Beyond vaccines, Moderna's therapeutic programs include systemic treatments targeting secreted and cell surface proteins, diverse cancer vaccines such as personalized, KRAS, and checkpoint therapies, intratumoral immuno-oncology agents, localized regenerative medicines, systemic intracellular therapeutics, and inhaled treatments for pulmonary conditions. The company has established numerous strategic alliances and collaborative agreements with leading organizations, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. Additionally, it holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 and headquartered in Cambridge, Massachusetts, the entity initially operated as Moderna Therapeutics, Inc., before officially adopting the name Moderna, Inc. in August 2018.
www.modernatx.comNo one on the platform currently holds 0QF.F.
No tracked institution reports a position in 0QF.F as of their last filing.
No one on the platform has traded 0QF.F yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -39.2% | 19.3% | ||||
| Profit Margin % | -145.2% | -42.4% | -176.8% | |||
| Free Cash Flow Margin % | -105.1% | -37.7% | -124.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.1B | +9.0% | $-8.23 | $-10.36–$-6.67 | — | 1 |
| 2027 | $2.4B | +13.8% | $-4.72 | $-5.95–$-3.83 | — | 1 |
| 2028 | $3.3B | +38.4% | $-2.79 | $-3.52–$-2.26 | — | 1 |
| 2029 | $5.5B | +68.1% | $0.50 | $0.40–$0.62 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $-1.78 | $-1.72 | +3.1% |
| 2026-05-01 | $-3.85 | $-2.94 | +23.5% |
| 2026-02-13 | $-2.17 | $-1.80 | +17.1% |
| 2025-11-06 | $-1.60 | $-0.44 | +72.6% |
| 2025-08-01 | $-2.54 | $-1.81 | +28.8% |
| 2025-05-01 | $-2.88 | $-2.29 | +20.5% |
| 2025-02-21 | $-2.59 | $-2.81 | -8.5% |
| 2024-11-07 | $-1.62 |
| $0.03 |
| +101.8% |
| $424M |
| — |
| BBZA.DEBB Biotech AG | $54.30 | -1.81% | $3.0B | — |
| BNN.DEBRAIN Biotech AG | $2.72 | -2.16% | $59M | — |
Source: Financial Modeling Prep · peers by sector/industry